ABVX vs CANF: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABVX and CANF share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABVX and CANF exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the pivotal Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo. Management has guided toward a U.S. FDA new drug application filing in late 2026, with a Phase 2b Crohn's disease readout expected around mid-2027.

Full ABVX guide

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company that trades in the US as an ADR on the NYSE American. Its platform is built on the A3 adenosine receptor (A3AR), a G-protein-coupled receptor that is highly expressed on inflammatory and cancer cells but has low expression in normal cells, which the company argues makes it a selective drug target across cancer, liver disease, and inflammatory conditions. Can-Fite has no approved products and generates essentially no product revenue; it is a research-and-development-stage business whose value rests entirely on its pipeline of small-molecule A3AR drug candidates and its ability to fund years of clinical trials. Its two lead candidates are Namodenoson, in Phase 3 for advanced liver cancer (hepatocellular carcinoma) with additional studies in MASH (a metabolic liver disease) and pancreatic cancer, and Piclidenoson, in a pivotal Phase 3 study for psoriasis.

Full CANF guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
• CANF drivers: Namodenoson liver-cancer (HCC) Phase 3 readout; Broader Namodenoson pipeline (MASH and pancreatic cancer).

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. For CANF, this is a highly speculative micro-cap with concentrated, binary risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABVX if you believe its drivers more; CANF if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABVX and CANF guides.

ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding pivotal trials rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.

CANF. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a pre-revenue biotech, traditional valuation metrics such as P/E do not apply, because there are no earnings; what matters is cash runway, the probability and timing of clinical readouts, and dilution. The small cash balance, recurring losses, dependence on dilutive financing, and a large reverse split all point to significant liquidity pressure, so the investment case is a speculative, binary bet on trial outcomes rather than on any current financial performance.

Headline figures (approximate, July 2026): ABVX shows market cap ~$7-8B, product revenue (ttm) ~negligible (pre-commercial), net loss (fy2025) ~EUR 336M, r&d expense (fy2025) ~EUR 178M; CANF shows revenue / earnings Pre-revenue clinical-stage company with no approved products; it reports recurring net losses, not profits, net loss (2025) approximately $9.8 million (versus about $7.9 million in 2024), accumulated deficit approximately $176 million as of December 31, 2025, cash position approximately $5.5 million cash plus about $3.0 million short-term deposits at December 31, 2025; management indicated roughly twelve months of runway from that point, with more capital needed thereafter.

ABVX and CANF are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABVX and CANF exposure against your real portfolio. It is not an investment adviser.